This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Ubiquinol
DrugBank Accession Number
DB11340
Background

Ubiquinol (CoQH2) is a reduced form of coenzyme Q10 (CoQ10) that acts as an active antioxidant that prevents the initiation and propagation of lipid peroxidation in biological membranes and human low-density lipoprotein (LDL). It plays an essential role in maintaining cellular defense against oxidative damage and also sustains the effects of vitamin E by regenerating the vitamin from the tocopheroxyl radical, but ubiquinol is not classified as a vitamin because it is synthesized by humans. There are varying concentrations of ubiquinol in foods, OTC products and dietary supplement products.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 865.3594
Monoisotopic: 864.699561432
Chemical Formula
C59H92O4
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Co-BalaminUbiquinol (200 mg/1mg) + Folic acid (0.8 mg/1mg) + Mecobalamin (5 mg/1mg) + Resveratrol (400 mg/1mg)CapsuleOralHome Aide Diagnostics, Inc.2015-08-01Not applicableUS flag
Co-VeratrolUbiquinol (200 mg/1mg) + Folic acid (0.8 mg/1mg) + Mecobalamin (5 mg/1mg) + Resveratrol (400 mg/1mg)CapsuleOralHome Aide Diagnostics, Inc.2015-08-012018-10-05US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as polyprenyl quinols. These are compounds containing a polyisoprene chain attached to a quinol(hydroquinone) at the second ring position.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Quinone and hydroquinone lipids
Direct Parent
Polyprenyl quinols
Alternative Parents
Polyterpenoids / 2-polyprenyl-6-methoxyphenols / Ubiquinols / Methoxyphenols / Dimethoxybenzenes / Phenoxy compounds / Ortho cresols / Meta cresols / Hydroquinones / Anisoles
show 3 more
Substituents
2-polyprenyl-6-methoxyphenol / Alkyl aryl ether / Anisole / Aromatic homomonocyclic compound / Benzenoid / Dimethoxybenzene / Ether / Hydrocarbon derivative / Hydroquinone / M-cresol
show 15 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
polyprenylhydroquinone, ubiquinol (CHEBI:64183)
Affected organisms
Not Available

Chemical Identifiers

UNII
M9NL0C577Y
CAS number
992-78-9
InChI Key
QNTNKSLOFHEFPK-UPTCCGCDSA-N
InChI
InChI=1S/C59H92O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42,60-61H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
IUPAC Name
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylbenzene-1,4-diol
SMILES
COC1=C(OC)C(O)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(C)=C1O

References

General References
  1. Ernster L, Forsmark-Andree P: Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig. 1993;71(8 Suppl):S60-5. [Article]
  2. Mohr D, Bowry VW, Stocker R: Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta. 1992 Jun 26;1126(3):247-54. [Article]
Human Metabolome Database
HMDB0013111
PubChem Compound
9962735
PubChem Substance
347827969
ChemSpider
8138335
RxNav
39085
ChEBI
64183
ZINC
ZINC000085574641
Wikipedia
Ubiquinol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentChronic Fatigue / Coenzyme Q10 / Gulf War Illness / Ubiquinol1
2CompletedOtherCardiac Arrest1
2CompletedOtherSepsis1
2CompletedTreatmentParkinson's Disease (PD)1
2Unknown StatusTreatmentHeart Failure1
2, 3CompletedTreatmentPolycystic Ovarian Syndrome (PCOS)1
1Not Yet RecruitingTreatmentOral Lichen Planus1
Not AvailableWithdrawnNot AvailableMyalgic Encephalomyelitis (ME)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000233 mg/mLALOGPS
logP9.68ALOGPS
logP18.23ChemAxon
logS-6.6ALOGPS
pKa (Strongest Acidic)10.27ChemAxon
pKa (Strongest Basic)-4.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.92 Å2ChemAxon
Rotatable Bond Count31ChemAxon
Refractivity286.45 m3·mol-1ChemAxon
Polarizability112.46 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at December 03, 2015 16:52 / Updated at June 12, 2020 16:53